Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ju-Hee Oh

Showing results (81-90 of 87) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 87 results.
Neuro-Oncology Advances|February 10, 2026
Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenograftsRachael A Vaubel, Wenjuan Zhang, Nishika Karbhari, et al.
Neuro-Oncology Advances|June 16, 2023
WSD-0922, a novel brain-penetrant inhibitor of epidermal growth factor receptor, promotes survival in glioblastoma mouse modelsJason E Conage-Pough, Sylwia A Stopka, Ju-Hee Oh, et al.
Nature Biotechnology|May 21, 2025
A multi-kingdom genetic barcoding system for precise clone isolationSoh Ishiguro, Kana Ishida, Rina C Sakata, et al.
Communications Biology|June 20, 2023
Blood-brain barrier disruption defines the extracellular metabolome of live human high-grade gliomasCecile Riviere-Cazaux, Lucas P Carlstrom, Karishma Rajani, et al.
Neuro-Oncology|September 8, 2025
Window of opportunity evaluation of blood-brain barrier permeability heterogeneity within and across high-grade glioma patientsJu-Hee Oh, Sarah K Reed, Cecile Riviere-Cazaux, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 2025
Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH-Wild-type GlioblastomaRachael A Vaubel, Wenjuan Zhang, Ju-Hee Oh, et al.
Neuro-Oncology|May 29, 2021
Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastomaBianca-Maria Marin, Kendra A Porath, Sonia Jain, et al.
Pageof 9

Showing results (81-90 of 87) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 87 results.
Neuro-Oncology Advances|February 10, 2026
Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenograftsRachael A Vaubel, Wenjuan Zhang, Nishika Karbhari, et al.
Neuro-Oncology Advances|June 16, 2023
WSD-0922, a novel brain-penetrant inhibitor of epidermal growth factor receptor, promotes survival in glioblastoma mouse modelsJason E Conage-Pough, Sylwia A Stopka, Ju-Hee Oh, et al.
Nature Biotechnology|May 21, 2025
A multi-kingdom genetic barcoding system for precise clone isolationSoh Ishiguro, Kana Ishida, Rina C Sakata, et al.
Communications Biology|June 20, 2023
Blood-brain barrier disruption defines the extracellular metabolome of live human high-grade gliomasCecile Riviere-Cazaux, Lucas P Carlstrom, Karishma Rajani, et al.
Neuro-Oncology|September 8, 2025
Window of opportunity evaluation of blood-brain barrier permeability heterogeneity within and across high-grade glioma patientsJu-Hee Oh, Sarah K Reed, Cecile Riviere-Cazaux, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 2025
Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH-Wild-type GlioblastomaRachael A Vaubel, Wenjuan Zhang, Ju-Hee Oh, et al.
Neuro-Oncology|May 29, 2021
Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastomaBianca-Maria Marin, Kendra A Porath, Sonia Jain, et al.
Pageof 9